THSTI-IAVI HIV Vaccine Design Program, Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad-Gurgaon Expressway, P.O. Box # 04, Faridabad-1221001, Haryana, India.
Department of Integrative Structural and Computational Biology, Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, International AIDS Vaccine Initiative Neutralizing Antibody Center and Collaboration for AIDS Vaccine Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA.
Vaccine. 2018 Mar 14;36(12):1627-1636. doi: 10.1016/j.vaccine.2018.01.081. Epub 2018 Feb 9.
Using HIV-1 envelope protein (Env)-based immunogens that closely mimic the conformation of functional HIV-1 Envs and represent the isolates prevalent in relevant geographical region is considered a rational approach towards developing HIV vaccine. We recently reported that like clade B Env, JRFL, membrane bound Indian clade C Env, 4-2.J41 is also efficiently cleaved and displays desirable antigenic properties for plasmid DNA immunization. Here, we evaluated the immune response in rabbit by injecting the animals with plasmid expressing membrane bound efficiently cleaved 4-2.J41 Env followed by its gp140-foldon (gp140-fd) protein boost. The purified 4-2.J41-gp140-fd protein is recognized by a wide panel of broadly neutralizing antibodies (bNAbs) including the quaternary conformation-dependent antibody, PGT145 with high affinity. We have also evaluated and compared the quality of antibody response elicited in rabbits after immunizing with plasmid DNA expressing the membrane bound efficiently cleaved Env followed by gp140-fd proteins boost with either of clade C Env, 4-2.J41 or clade B Env, JRFL or in combination. In comparison to JRFL group, 4-2.J41 group elicited autologous as well as limited low level cross clade neutralizing antibody response. Preliminary epitope-mapping of sera from animals show that in contrast to JRFL group, no reactivity to either linear peptides or V3-loop is detected in 4-2.J41 group. Furthermore, the presence of conformation-specific antibody in sera from animals immunized with 4-2.J41 Env is observed. However, unlike JRFL group, in 4-2.J41 group of animals, CD4-binding site-directed antibodies cannot be detected. Additionally, we have demonstrated that the quality of antibody response in combination group is guided by JRFL Env-based immunogen suggesting that the selection and the quality of Envs in multicade candidate vaccine are important factors to elicit desirable response.
使用能够模拟功能性 HIV-1 包膜蛋白(Env)构象并代表相关地理区域流行株的基于 HIV-1 Env 的免疫原,被认为是开发 HIV 疫苗的合理方法。我们最近报道称,与 clade B Env 一样,JRFL、膜结合的印度 clade C Env 4-2.J41 也能有效地被切割,并具有用于质粒 DNA 免疫的理想抗原特性。在这里,我们通过注射表达膜结合的高效切割 4-2.J41 Env 的质粒来评估兔子的免疫反应,然后进行其 gp140 折叠蛋白(gp140-fd)的蛋白增强。纯化的 4-2.J41-gp140-fd 蛋白被广泛的中和抗体(bNAbs)识别,包括具有高度亲和力的四级构象依赖性抗体 PGT145。我们还评估和比较了用表达膜结合的高效切割 Env 的质粒 DNA 免疫后,在兔子中引发的抗体反应的质量,然后用 clade C Env 的 gp140-fd 蛋白进行增强,无论是 4-2.J41 还是 clade B Env JRFL,或者两者结合。与 JRFL 组相比,4-2.J41 组引发了自体和有限的低水平交叉 clade 中和抗体反应。来自动物的血清的初步表位作图显示,与 JRFL 组不同,在 4-2.J41 组中未检测到对线性肽或 V3 环的反应。此外,在 4-2.J41 Env 免疫的动物血清中观察到构象特异性抗体的存在。然而,与 JRFL 组不同,在 4-2.J41 组的动物中,不能检测到 CD4 结合位点定向抗体。此外,我们已经证明,组合组中的抗体反应质量受到 JRFL Env 免疫原的指导,这表明多 clade 候选疫苗中 Env 的选择和质量是引发理想反应的重要因素。